A recent paper published in the BMJ queried the assessment of the ROCKET AF study that the drug Rivaroxaban is effective in reducing Atrial Fibrillation (AF) related stroke. The group who undertook the ROCKET AF study reviewed their data and have now published their finding in the New England Journal of Medicine that Rivaroxaban does not show any increased bleeding risk compared to warfarin. The European Medicines Agency (EMA) concluded the device in the ROCKET AF study did not impact the safety of the drug.
Alexis Wieroniey, Deputy Director for Policy and Influencing at the Stroke Association said;
“It is very important that medical studies are scrutinised and accountable as all drug therapies carry risk. However, the concerns raised about Rivaroxaban have not affected the licensed use of the drug nor changed the clinical information on its efficacy and safety.
“People taking Rivaroxaban should continue taking their medication to reduce their risk of stroke. If anyone is concerned about Rivaroxaban, they should contact their GP or specialist who should be able to discuss this in more detail for their particular case.”